GTBP · Forms 3, 4, 5
Insider trades at GT Biopharma, Inc.
No open-market insider buys or sells at GT Biopharma, Inc. in the last 90 days; 9 filings reported awards, option exercises, tax withholding or new insiders.
Every Form 3, 4 and 5 filed for GT Biopharma, Inc. (GTBP) with the SEC, newest first: who traded, their role, buy or sell, shares, price and value.
Most recent insider filings
No Form 3, 4 or 5 filings for GT Biopharma, Inc. in the last 90 days. The latest ones on EDGAR:
| Date | Insider | Role | Transaction | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| David C. Mun-Gavin | Director | Options or other derivatives | Form 4 | ||||
| Michael Martin Breen | CEO and Director | Options or other derivatives | Form 4 | ||||
| Alan Louis Urban | Chief Financial Officer | Options or other derivatives | Form 4 | ||||
| Charles J Casamento | Director | Options or other derivatives | Form 4 | ||||
| Hilary Kramer | Director | Options or other derivatives | Form 4 | ||||
| David C. Mun-Gavin | Director | Became an insider (Form 3) | Form 3 | ||||
| Hilary Kramer | Director | Became an insider (Form 3) | Form 3 | ||||
| Andrew J Ritter | Director | Became an insider (Form 3) | Form 3 | ||||
| Alan Louis Urban | Chief Financial Officer | Options or other derivatives | Form 4 |
Buy and Sell are open-market purchases and sales (transaction codes P and S), the trades investors watch. Awards, option exercises, tax withholding and gifts are reported too but are not market trades.